Skip to main content
. 2021 Aug 27;2(9):100383. doi: 10.1016/j.xcrm.2021.100383

Figure 3.

Figure 3

Kaplan-Meier plots of progression-free survival, overall survival, and duration of response

(A and B) Kaplan-Meier plot (A) of progression-free survival (PFS) and Kaplan-Meier plot (B) of overall survival (OS) in 33 patients with regorafenib 80 mg as recommended dose.

(C) Kaplan-Meier plot of duration of response (DOR) in 5 patients with partial response.